Відмінності між версіями «Primarily based sexual wellness interventions to prevent STI/HIV in sub-Saharan Africa.»

Поточна версія на 02:17, 29 березня 2018

2004 Jan ten; 328(7431): 70.doi: 10.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ title= peds.2015-0966 Publishing Group Ltd.A pledge last month by Swiss pharmaceuticals giant Novartis to donate 7m (��3.9m; �?.5m) worth of drugs to 500 000 individuals with tuberculosis in poor nations more than the subsequent 5 years has raised hopes that other drug companies will adhere to suit to fight HIV/AIDS and malaria.Under an agreement together with the Globe Wellness Organization on 19 December, Novartis will provide drugs to assist poor nations receive and distribute drugs to Sm of action as they block L-type Ca2+ channels, the question patients with tuberculosis. In place of taking four separate pills per day, patients take a single pill containing 4 different drugs for two months and a single pill containing two drugs for four months.This is anticipated to maintain counterfeit drugs out of your chain and lessen the burden on healthcare workers, who will now only want to offer sufferers access to their daily dose and make a note that they have taken it. And it will be a lot easier for individuals to stick to their therapy.The fixed combination drug strategy is central to WHO's target of supplying antiretroviral drugs to some 3 million patients with HIV/AIDS in poor countries by 2005, but so far it has been unclear how such big title= fnint.2013.00038 supplies of those drugs would be financed. In contrast to tuberculosis, the therapy does not stop soon after six months, and, as it is most likely to be hard to have funding, any arrangement is most likely to set a precedent.Novartis will manufacture the fixed mixture antituberculosis drug in India. These will be administered under the DOTS (directly observed short course) method of strict surveillance to prevent individuals from stopping therapy, which can result in a number of drug resistant tuberculosis strains."Novartis has come to be a major force within the fight against tuberculosis," stated Dr Lee Jong-wook, WHO's director common.Primarily based sexual overall health interventions to prevent STI/HIV in sub-Saharan Africa. BMC Public Overall health 2008, 8(4):1?3.doi:10.1186/1471-2458-14-54 Cite this article as: Aar?et al.: Promoting sexual and reproductive well being among adolescents in southern and eastern Africa (PREPARE): project design and style and conceptual framework. BMC Public Well being 2014 14:54.Submit your next manuscript to BioMed Central and take complete advantage of:?Hassle-free on-line submission ?Thorough peer overview ?No space constraints or color figure charges ?Quick publication on acceptance ?Inclusion in PubMed, CAS, Scopus title= s40037-015-0222-8 and Google Scholar ?Investigation that is freely accessible for redistributionSubmit your manuscript at www.biomedcentral.com/submit BMJ. 2004 Jan ten; 328(7431): 70.doi: 10.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ title= peds.2015-0966 Publishing Group Ltd.A pledge last month by Swiss pharmaceuticals giant Novartis to donate 7m (��3.9m; �?.5m) worth of drugs to 500 000 individuals with tuberculosis in poor nations over the following five years has raised hopes that other drug businesses will stick to suit to fight HIV/AIDS and malaria.Beneath an agreement with the Planet Health Organization on 19 December, Novartis will give drugs to help poor countries get and distribute drugs to individuals with tuberculosis.